±¤µ¿¾ÏÇмú»ó¿¡ ÀÓÈ£¿µ¡¤ÀÌÁ¾¼ö¡¤³²ÁÖÇö ±³¼ö ¼ö»ó

´º½ºÀÏÀÚ: 2013³â06¿ù19ÀÏ 10½Ã52ºÐ

►»çÁø-¿ÞÂʺÎÅÍ ÀÓÈ£¿µ,ÀÌÁ¾¼ö,³²ÁÖÇö ±³¼ö

´ëÇѾÏÇÐȸ°¡ ¼±Á¤, ¼ö¿©ÇÏ´Â ‘±¤µ¿¾ÏÇмú»ó' ¼ö»óÀÚ·Î ÀÓÈ£¿µ ±³¼ö(¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇÐ), ÀÌÁ¾¼ö ±³¼ö(¾ÆÁÖ´ëÇб³ ÀÚ¿¬°úÇдëÇÐ »ý¸í°úÇÐÀü°ø), ³²ÁÖÇö ±³¼ö(¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ »êºÎÀΰúÇÐ)°¡ ¼±Á¤µÆ´Ù.
 
´ëÇѾÏÇÐȸ(ȸÀå À强±¸)´Â ÃÖ±Ù ¼­¿ï ¼Ò°øµ¿ ·Ôµ¥È£ÅÚ¿¡¼­ ¿­¸° Á¦39ȸ ´ëÇѾÏÇÐȸ Á¤±âÃÑȸ¿¡¼­ ÀÓÈ£¿µ ±³¼ö, ÀÌÁ¾¼ö ±³¼ö, ³²ÁÖÇö ±³¼ö¿¡°Ô ±¤µ¿¾ÏÇмú»óÀ» ¼ö¿©Çß´Ù°í ¹àÇû´Ù.
 
´ëÇѾÏÇÐȸ¿Í ±¤µ¿Á¦¾àÀÌ °øµ¿ Á¦Á¤ÇÑ ±¤µ¿¾ÏÇмú»óÀº ¼öÁØÀÌ SCI Àú³Î ȤÀº ºÐ¾ßº° SCI ³í¹®ÀÇ ºñÀ²ÀÌ °¡Àå ³ôÀº ÇÐȸÁö¿¡ ¾ÏÇÐȸÁö¸¦ ÀοëÇÑ ³í¹®À» ¹ßÇ¥ÇÑ ¿¬±¸ÀÚ, ±×¸®°í ´Ù¼öÀÇ SCI Àú³Î¿¡ ¾ÏÇÐȸÁö¸¦ ÀοëÇØ ¹ßÇ¥ÇÑ ¿¬±¸ÀÚ µî ¾Ï Ä¡·á °³¼±¿¡ Ź¿ùÇÑ ¿¬±¸ ¾÷ÀûÀ» ³½ ÀÇÇÐÀÚ¿¡°Ô ¼ö¿©ÇÏ´Â »óÀÌ´Ù.

´ëÇѾÏÇÐȸ »óÀÓÀ§¿øȸ ½É»ç¸¦ ÅëÇØ ÃÖÁ¾ ¼ö»óÀÚ¸¦ ¼±Á¤Çϸç, ¼ö»óÀÚ¿¡°Ô´Â 500¸¸¿øÀÇ »ó±Ý°ú »óÀåÀ» ¼ö¿©ÇÑ´Ù.
 
ÃÖ°í ¿µÇâ·ÂÁö¼ö (IF, Impact Factor) SCI Àú³ÎÀÇ Àӻ󿬱¸ ³í¹® ¹ßÇ¥·Î´Â ÀÓÈ£¿µ ±³¼ö°¡ LANCET ONCOL(IF 22.589)¿¡ ³í¹®(citabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study)À» °ÔÀçÇßÀ¸¸ç, ±âÃÊ¿¬±¸ ³í¹® ¹ßÇ¥·Î´Â ÀÌÁ¾¼ö ±³¼ö°¡ NUCLEIC ACIDS RES(IF 8.026)¿¡ ³í¹®(Suppression and recovery of BRCA1-mediated transcription by HP1 gamma via modulation of promoter occupancy)À» °ÔÀçÇß´Ù.

³² ±³¼ö´Â ¸ðµÎ 4ÆíÀÇ SCI Àú³Î¿¡ ´ëÇѾÏÇÐȸÁö¸¦ ÀοëÇØ ³í¹®À» °ÔÀçÇÔÀ¸·Î½á ±¹³» ÃÖ°í±ÇÀ§ÀÇ ¾ÏÇÐȸÁö°¡ ¸í½Ç »óºÎÇÑ ±¹Á¦Àú³Î·Î µµ¾àÇϴµ¥ ±â¿©Çß´Ù.
 
´ëÇѾÏÇÐȸ °ü°èÀÚ´Â "±¤µ¿¾ÏÇмú»óÀº ¾Ï Ä¡·á ºÐ¾ßÀÇ ±âÃÊ-ÀÓ»ó ¿¬±¸¿¡ È°±â¸¦ ºÒ¾î³Ö°í ÀÖ´Ù.”¸ç “Çѱ¹ ÀÇÇÐÀÇ ±¹Á¦Àû À§»ó Á¤¸³¿¡ ±â¿©ÇÒ ¼ö Àֱ⸦ ±â´ëÇÑ´Ù"°í ¹àÇû´Ù.

 

 

 

 

 


ÀÌ ´º½ºÅ¬¸®ÇÎÀº BKT´º½º{www.bktimes.net}¿¡¼­ ¹ßÃéµÈ ³»¿ëÀÔ´Ï´Ù.